# A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

> **NCT06639087** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 8 (actual)

## Conditions studied

- Renal Impairment
- Heart Failure

## Interventions

- **DRUG:** AZD5462
- **DRUG:** Dapagliflozin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06639087
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-27
- **Primary completion:** 2025-05-29
- **Final completion:** 2025-05-29
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06639087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06639087, "A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06639087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*